Taken together, our results indicate that lack of ADAM17 in the skin results in dermatitis and myeloproliferative disease, which validates previous findings by Franzke et al. 20 that ADAM17 maintains the skin barrier. Here, ADAM17 is linked to myeloproliferative disorder.